 Katharine Yao
Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mastectomy | 45 | 2022 | 217 | 15.330 |
Why?
| | Breast Neoplasms | 80 | 2022 | 2699 | 15.220 |
Why?
| | Carcinoma, Ductal, Breast | 21 | 2019 | 151 | 7.550 |
Why?
| | Carcinoma, Lobular | 18 | 2019 | 78 | 6.920 |
Why?
| | Mastectomy, Segmental | 15 | 2022 | 88 | 4.060 |
Why?
| | Neoadjuvant Therapy | 8 | 2019 | 265 | 3.310 |
Why?
| | Neoplasm Staging | 25 | 2019 | 1858 | 2.930 |
Why?
| | Mammaplasty | 9 | 2022 | 94 | 2.740 |
Why?
| | Quality Indicators, Health Care | 5 | 2021 | 130 | 2.380 |
Why?
| | Lymph Node Excision | 10 | 2021 | 197 | 2.300 |
Why?
| | Sentinel Lymph Node Biopsy | 12 | 2021 | 55 | 2.220 |
Why?
| | Cancer Care Facilities | 3 | 2020 | 26 | 2.170 |
Why?
| | Radiation Oncology | 3 | 2021 | 117 | 2.150 |
Why?
| | Databases, Factual | 18 | 2018 | 756 | 2.090 |
Why?
| | Accreditation | 3 | 2019 | 51 | 2.060 |
Why?
| | Prognosis | 25 | 2020 | 3522 | 2.060 |
Why?
| | Receptors, Estrogen | 9 | 2019 | 375 | 2.040 |
Why?
| | Middle Aged | 62 | 2022 | 23948 | 2.000 |
Why?
| | Female | 83 | 2022 | 42244 | 1.960 |
Why?
| | Practice Guidelines as Topic | 7 | 2019 | 1030 | 1.880 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 6 | 2016 | 106 | 1.840 |
Why?
| | Guideline Adherence | 4 | 2018 | 215 | 1.810 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2020 | 1156 | 1.800 |
Why?
| | Follow-Up Studies | 21 | 2020 | 3553 | 1.750 |
Why?
| | Aged, 80 and over | 33 | 2018 | 6195 | 1.710 |
Why?
| | Chemotherapy, Adjuvant | 8 | 2019 | 441 | 1.700 |
Why?
| | Aged | 48 | 2021 | 17394 | 1.680 |
Why?
| | Radiotherapy, Adjuvant | 9 | 2021 | 284 | 1.670 |
Why?
| | Mastectomy, Subcutaneous | 2 | 2022 | 7 | 1.580 |
Why?
| | Nipples | 6 | 2022 | 35 | 1.530 |
Why?
| | Humans | 90 | 2022 | 79512 | 1.530 |
Why?
| | Receptor, erbB-2 | 5 | 2019 | 182 | 1.440 |
Why?
| | Thoracic Wall | 2 | 2018 | 22 | 1.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2277 | 1.340 |
Why?
| | Lymph Nodes | 4 | 2018 | 507 | 1.340 |
Why?
| | Neoplasm Invasiveness | 9 | 2020 | 512 | 1.240 |
Why?
| | Adult | 42 | 2021 | 24525 | 1.240 |
Why?
| | Decision Support Techniques | 2 | 2019 | 154 | 1.240 |
Why?
| | United States | 26 | 2022 | 6050 | 1.240 |
Why?
| | Combined Modality Therapy | 8 | 2021 | 1602 | 1.190 |
Why?
| | Decision Making | 4 | 2019 | 595 | 1.180 |
Why?
| | Retrospective Studies | 23 | 2020 | 7386 | 1.140 |
Why?
| | Breast | 6 | 2021 | 265 | 1.130 |
Why?
| | Axilla | 11 | 2021 | 92 | 1.120 |
Why?
| | Receptors, Progesterone | 6 | 2019 | 163 | 1.110 |
Why?
| | Neoplasms, Second Primary | 3 | 2017 | 242 | 1.100 |
Why?
| | Survival Rate | 12 | 2018 | 1809 | 1.070 |
Why?
| | Carcinoma | 2 | 2017 | 412 | 0.970 |
Why?
| | Brachytherapy | 2 | 2014 | 115 | 0.960 |
Why?
| | Breast Neoplasms, Male | 1 | 2022 | 28 | 0.940 |
Why?
| | Organ Sparing Treatments | 2 | 2019 | 34 | 0.920 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 625 | 0.890 |
Why?
| | Neoplasm Grading | 10 | 2018 | 319 | 0.870 |
Why?
| | Quality of Health Care | 3 | 2018 | 360 | 0.820 |
Why?
| | Burnout, Professional | 1 | 2021 | 78 | 0.770 |
Why?
| | Healthcare Disparities | 2 | 2015 | 325 | 0.760 |
Why?
| | Lymphatic Metastasis | 7 | 2018 | 465 | 0.750 |
Why?
| | Age Factors | 9 | 2018 | 1797 | 0.740 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2017 | 146 | 0.730 |
Why?
| | Stereotaxic Techniques | 1 | 2019 | 69 | 0.720 |
Why?
| | Patient Satisfaction | 4 | 2016 | 422 | 0.710 |
Why?
| | Patient Selection | 6 | 2019 | 662 | 0.700 |
Why?
| | Reoperation | 5 | 2015 | 562 | 0.700 |
Why?
| | Consensus | 2 | 2016 | 288 | 0.690 |
Why?
| | Coronavirus Infections | 2 | 2020 | 283 | 0.690 |
Why?
| | Patient Care | 1 | 2019 | 88 | 0.690 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 302 | 0.690 |
Why?
| | Patient Transfer | 1 | 2018 | 90 | 0.680 |
Why?
| | Genes, BRCA2 | 3 | 2016 | 147 | 0.670 |
Why?
| | Radiography, Interventional | 1 | 2019 | 148 | 0.670 |
Why?
| | Genes, BRCA1 | 3 | 2016 | 185 | 0.660 |
Why?
| | Young Adult | 12 | 2021 | 5701 | 0.650 |
Why?
| | Patient Acceptance of Health Care | 2 | 2017 | 217 | 0.650 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 87 | 0.640 |
Why?
| | Patient Preference | 4 | 2019 | 103 | 0.620 |
Why?
| | Logistic Models | 7 | 2017 | 1113 | 0.620 |
Why?
| | Postoperative Complications | 7 | 2016 | 2067 | 0.610 |
Why?
| | Societies, Medical | 2 | 2019 | 565 | 0.590 |
Why?
| | Quality of Life | 4 | 2019 | 1342 | 0.570 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2019 | 488 | 0.560 |
Why?
| | Prospective Studies | 8 | 2022 | 3870 | 0.560 |
Why?
| | Estrogen Receptor alpha | 2 | 2013 | 138 | 0.540 |
Why?
| | Patient Education as Topic | 1 | 2016 | 340 | 0.500 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 1367 | 0.480 |
Why?
| | Length of Stay | 3 | 2015 | 647 | 0.470 |
Why?
| | Melanoma | 2 | 2009 | 426 | 0.470 |
Why?
| | Receptors, Notch | 2 | 2010 | 116 | 0.470 |
Why?
| | Skin Neoplasms | 2 | 2009 | 510 | 0.450 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2013 | 181 | 0.450 |
Why?
| | Registries | 1 | 2014 | 648 | 0.430 |
Why?
| | Patient Readmission | 1 | 2014 | 287 | 0.410 |
Why?
| | Receptor, Notch1 | 2 | 2010 | 80 | 0.410 |
Why?
| | Workload | 2 | 2022 | 125 | 0.410 |
Why?
| | Operating Rooms | 2 | 2022 | 118 | 0.410 |
Why?
| | Adolescent | 7 | 2021 | 8657 | 0.390 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2008 | 3 | 0.370 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 535 | 0.350 |
Why?
| | Breast Diseases | 1 | 2008 | 96 | 0.350 |
Why?
| | Quality Control | 2 | 2019 | 112 | 0.340 |
Why?
| | Breast Implantation | 3 | 2016 | 10 | 0.330 |
Why?
| | Calcinosis | 1 | 2008 | 232 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 2 | 2010 | 642 | 0.320 |
Why?
| | Pilot Projects | 3 | 2019 | 796 | 0.310 |
Why?
| | SEER Program | 3 | 2017 | 179 | 0.310 |
Why?
| | Risk Factors | 6 | 2019 | 5099 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2017 | 803 | 0.300 |
Why?
| | Multivariate Analysis | 4 | 2018 | 962 | 0.290 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3069 | 0.280 |
Why?
| | Health Care Surveys | 2 | 2018 | 275 | 0.280 |
Why?
| | Risk Assessment | 4 | 2020 | 2158 | 0.280 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 823 | 0.280 |
Why?
| | Referral and Consultation | 2 | 2019 | 304 | 0.270 |
Why?
| | Biopsy | 3 | 2014 | 1117 | 0.250 |
Why?
| | Time Factors | 5 | 2016 | 5143 | 0.240 |
Why?
| | Radiotherapy Dosage | 2 | 2014 | 480 | 0.230 |
Why?
| | Cohort Studies | 4 | 2018 | 2561 | 0.210 |
Why?
| | Pandemics | 3 | 2022 | 555 | 0.210 |
Why?
| | Male | 8 | 2022 | 39419 | 0.200 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1322 | 0.200 |
Why?
| | Mammography | 2 | 2017 | 451 | 0.200 |
Why?
| | Personnel Selection | 1 | 2020 | 52 | 0.190 |
Why?
| | Longitudinal Studies | 2 | 2020 | 947 | 0.190 |
Why?
| | Specialties, Surgical | 1 | 2020 | 59 | 0.190 |
Why?
| | Health Resources | 1 | 2020 | 73 | 0.190 |
Why?
| | Fear | 1 | 2019 | 66 | 0.190 |
Why?
| | Triage | 1 | 2020 | 97 | 0.190 |
Why?
| | Body Image | 1 | 2019 | 79 | 0.190 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2022 | 248 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2018 | 7469 | 0.190 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 94 | 0.190 |
Why?
| | Breast Implants | 2 | 2016 | 20 | 0.190 |
Why?
| | Interviews as Topic | 1 | 2020 | 314 | 0.180 |
Why?
| | Anxiety | 1 | 2021 | 250 | 0.180 |
Why?
| | User-Computer Interface | 1 | 2020 | 184 | 0.180 |
Why?
| | Video Recording | 1 | 2019 | 184 | 0.180 |
Why?
| | Neoplasm Micrometastasis | 1 | 2018 | 4 | 0.180 |
Why?
| | Databases as Topic | 1 | 2018 | 89 | 0.180 |
Why?
| | Emotions | 1 | 2021 | 303 | 0.170 |
Why?
| | Telemedicine | 1 | 2020 | 138 | 0.170 |
Why?
| | Patient Participation | 1 | 2019 | 194 | 0.170 |
Why?
| | Patient Compliance | 1 | 2018 | 220 | 0.160 |
Why?
| | Heterozygote | 2 | 2016 | 352 | 0.160 |
Why?
| | Choice Behavior | 1 | 2018 | 155 | 0.160 |
Why?
| | Sleep | 1 | 2021 | 411 | 0.160 |
Why?
| | Odds Ratio | 1 | 2018 | 647 | 0.160 |
Why?
| | Surgical Wound Infection | 2 | 2015 | 171 | 0.160 |
Why?
| | Ultrasonography, Mammary | 1 | 2017 | 82 | 0.150 |
Why?
| | Disease Management | 1 | 2018 | 323 | 0.150 |
Why?
| | Esthetics | 1 | 2016 | 49 | 0.150 |
Why?
| | Watchful Waiting | 1 | 2016 | 48 | 0.150 |
Why?
| | Illinois | 1 | 2017 | 446 | 0.150 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 190 | 0.150 |
Why?
| | Comprehension | 1 | 2016 | 67 | 0.150 |
Why?
| | Molecular Typing | 1 | 2015 | 15 | 0.150 |
Why?
| | Europe | 1 | 2016 | 293 | 0.150 |
Why?
| | Physicians | 2 | 2019 | 588 | 0.150 |
Why?
| | Pharyngectomy | 1 | 2015 | 8 | 0.140 |
Why?
| | Remission Induction | 1 | 2017 | 701 | 0.140 |
Why?
| | Patients | 1 | 2016 | 88 | 0.140 |
Why?
| | Population Surveillance | 1 | 2016 | 218 | 0.140 |
Why?
| | Counseling | 1 | 2016 | 135 | 0.140 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1722 | 0.140 |
Why?
| | Colorectal Neoplasms | 1 | 2022 | 842 | 0.140 |
Why?
| | Carcinoma in Situ | 1 | 2015 | 52 | 0.140 |
Why?
| | Selection Bias | 1 | 2014 | 36 | 0.140 |
Why?
| | Linear Models | 1 | 2015 | 401 | 0.130 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 292 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2018 | 1722 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 1032 | 0.130 |
Why?
| | Incidence | 2 | 2017 | 1528 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 418 | 0.130 |
Why?
| | Adipokines | 1 | 2013 | 18 | 0.130 |
Why?
| | Insurance, Health | 1 | 2014 | 145 | 0.130 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2015 | 120 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 845 | 0.120 |
Why?
| | Fatty Acids | 1 | 2013 | 123 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 115 | 0.120 |
Why?
| | Surgical Flaps | 1 | 2015 | 246 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2013 | 234 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2014 | 367 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2017 | 2570 | 0.100 |
Why?
| | Head and Neck Neoplasms | 1 | 2017 | 997 | 0.100 |
Why?
| | Models, Biological | 1 | 2018 | 1724 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 1163 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2112 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2010 | 111 | 0.100 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2010 | 176 | 0.090 |
Why?
| | African Americans | 2 | 2017 | 1076 | 0.090 |
Why?
| | Receptor Cross-Talk | 1 | 2008 | 32 | 0.090 |
Why?
| | False Positive Reactions | 1 | 2008 | 217 | 0.090 |
Why?
| | Hemostatics | 1 | 2008 | 52 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 63 | 0.090 |
Why?
| | Interferon-alpha | 1 | 2009 | 234 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 1025 | 0.090 |
Why?
| | Biopsy, Needle | 1 | 2008 | 233 | 0.090 |
Why?
| | Hyperplasia | 1 | 2008 | 141 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 359 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2009 | 152 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2009 | 157 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 172 | 0.080 |
Why?
| | Obesity | 1 | 2013 | 907 | 0.080 |
Why?
| | RNA, Messenger | 1 | 2012 | 1920 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2008 | 899 | 0.080 |
Why?
| | Disease-Free Survival | 2 | 2011 | 1175 | 0.070 |
Why?
| | Neoplasms | 1 | 2018 | 2618 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1937 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2010 | 1161 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 1618 | 0.060 |
Why?
| | Mutation | 1 | 2014 | 3745 | 0.060 |
Why?
| | Immunoenzyme Techniques | 2 | 2013 | 301 | 0.060 |
Why?
| | Organizational Innovation | 1 | 2020 | 35 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 1039 | 0.050 |
Why?
| | Fees and Charges | 1 | 2018 | 13 | 0.050 |
Why?
| | Hospital Charges | 1 | 2018 | 28 | 0.050 |
Why?
| | Program Evaluation | 1 | 2020 | 285 | 0.040 |
Why?
| | Quality Improvement | 1 | 2022 | 359 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 337 | 0.040 |
Why?
| | Propensity Score | 1 | 2018 | 133 | 0.040 |
Why?
| | Urologic Surgical Procedures | 1 | 2018 | 99 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 334 | 0.040 |
Why?
| | Postoperative Care | 1 | 2017 | 206 | 0.040 |
Why?
| | Tumor Burden | 1 | 2017 | 273 | 0.040 |
Why?
| | Chicago | 1 | 2020 | 1327 | 0.040 |
Why?
| | ROC Curve | 1 | 2018 | 734 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2013 | 1540 | 0.030 |
Why?
| | Prostatectomy | 1 | 2018 | 436 | 0.030 |
Why?
| | Self Report | 1 | 2016 | 269 | 0.030 |
Why?
| | Communication | 1 | 2018 | 398 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2015 | 112 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2015 | 147 | 0.030 |
Why?
| | Serpins | 1 | 2013 | 26 | 0.030 |
Why?
| | Lipase | 1 | 2013 | 21 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 316 | 0.030 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 60 | 0.030 |
Why?
| | Leptin | 1 | 2013 | 98 | 0.030 |
Why?
| | Risk | 1 | 2015 | 669 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 576 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 57 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2012 | 93 | 0.030 |
Why?
| | Eye Proteins | 1 | 2013 | 122 | 0.030 |
Why?
| | Sepsis | 1 | 2015 | 264 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2012 | 349 | 0.030 |
Why?
| | Comorbidity | 1 | 2015 | 907 | 0.030 |
Why?
| | Body Mass Index | 1 | 2013 | 740 | 0.020 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.020 |
Why?
| | Estradiol | 1 | 2008 | 246 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 441 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 764 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 537 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2008 | 1038 | 0.020 |
Why?
| | Mice | 1 | 2008 | 10710 | 0.010 |
Why?
| | Animals | 1 | 2008 | 25594 | 0.010 |
Why?
|
|
Yao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|